Intellectual Property Licensing
•217 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (217)
| Company | Market Cap | Price |
|---|---|---|
|
DIS
The Walt Disney Company
Disney monetizes its extensive IP portfolio via Intellectual Property Licensing agreements.
|
$205.09B |
$114.32
+0.22%
|
|
QCOM
QUALCOMM Incorporated
Intellectual Property Licensing accurately reflects QTL's long-term, high-margin IP licensing revenue model.
|
$190.24B |
$182.03
+3.25%
|
|
ARM
Arm Holdings plc American Depositary Shares
Arm's primary revenue is intellectual property licensing for chip designs.
|
$122.38B |
$115.97
-0.12%
|
|
SNPS
Synopsys, Inc.
The company licenses intellectual property (design IP) as a core revenue stream.
|
$91.80B |
$506.98
+2.59%
|
|
TTWO
Take-Two Interactive Software, Inc.
Intellectual property licensing of TTWO's game IP/assets to partners is a distinct license-based revenue stream.
|
$47.47B |
$255.05
-0.88%
|
|
TKO
TKO Group Holdings, Inc.
Intellectual property licensing as a broader category for IP monetization.
|
$40.38B |
$202.67
-0.48%
|
|
ERIC
Telefonaktiebolaget LM Ericsson (publ)
Intellectual Property Licensing represents a key monetization channel via IPR licensing of Ericsson's technology.
|
$31.90B |
$9.54
+0.05%
|
|
FSLR
First Solar, Inc.
Licensing and enforcement of intellectual property (TOPCon patent portfolio) with licensing revenue.
|
$29.17B |
$271.25
-0.28%
|
|
CRDO
Credo Technology Group Holding Ltd
The company also participates in IP licensing revenue, which maps to Intellectual Property Licensing.
|
$24.26B |
$134.91
-3.80%
|
|
RPRX
Royalty Pharma plc
Royalties arise from intellectual property licensing of biopharma assets.
|
$23.12B |
$40.46
+2.04%
|
|
GFS
GLOBALFOUNDRIES Inc.
GF's acquisition of MIPS adds IP licensing revenue through RISC-V processor IP and related software tools.
|
$20.52B |
$39.56
+6.54%
|
|
XPEV
XPeng Inc.
Intellectual Property Licensing — IP licensing revenue from collaborations with Volkswagen.
|
$19.08B |
$20.09
-0.27%
|
|
WMG
Warner Music Group Corp.
WMG engages in intellectual property licensing related to its music catalogs and IP assets.
|
$16.02B |
$30.54
-0.65%
|
|
GWRE
Guidewire Software, Inc.
Intellectual Property Licensing as Guidewire licenses software/IP to customers.
|
$15.72B |
$187.76
+0.98%
|
|
NWS
News Corporation
Intellectual property licensing of IP assets to partners in AI/content domains.
|
$14.80B |
$29.95
+0.18%
|
|
LYB
LyondellBasell Industries N.V.
LYB licenses polyolefin process technologies and sells catalysts, constituting intellectual property licensing activity.
|
$14.66B |
$45.86
+0.59%
|
|
ROIV
Roivant Sciences Ltd.
Genevant's LNP/IP licensing revenue supports Intellectual Property Licensing.
|
$14.55B |
$21.46
+0.77%
|
|
HAS
Hasbro, Inc.
Hasbro monetizes intellectual property through licensing arrangements across media, entertainment, and consumer products.
|
$12.00B |
$87.25
+1.95%
|
|
RMBS
Rambus Inc.
Derives revenue from Intellectual Property Licensing, including silicon IP cores (HBM4 IP, PCIe 7 IP).
|
$10.49B |
$98.06
+0.57%
|
|
SARO
StandardAero, Inc.
Licensing of engine platform IP (CF34) and related technology.
|
$10.16B |
$30.38
+0.03%
|
|
IDCC
InterDigital, Inc.
InterDigital's core business is licensing its large patent portfolio (wireless, video, and AI technologies) to device makers and other partners, i.e., an Intellectual Property Licensing business.
|
$8.67B |
$310.67
-7.49%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme licenses its MDASE technology and related hyaluronidase IP (i.e., IP Licensing) to partners.
|
$8.33B |
$73.55
+3.29%
|
|
QS
QuantumScape Corporation
QuantumScape monetizes its development through Intellectual Property Licensing, including licensing agreements and royalty arrangements with automotive partners.
|
$6.41B |
$11.41
+0.71%
|
|
DLB
Dolby Laboratories, Inc.
Dolby's core revenue is through licensing its intellectual property and patents (e.g., Atmos, Vision), which fits Intellectual Property Licensing.
|
$6.12B |
$64.56
+1.14%
|
|
MNSO
MINISO Group Holding Limited
MINISO emphasizes developing proprietary IP and licensing IP across markets, a key driver of growth.
|
$6.07B |
$19.84
+1.41%
|
|
VICR
Vicor Corporation
Vicor actively licenses IP and has realized licensing settlements, a material revenue stream.
|
$6.00B |
$138.62
+3.72%
|
|
OLED
Universal Display Corporation
Licensing revenue is a core business model, via Intellectual Property Licensing.
|
$5.86B |
$126.76
+2.88%
|
|
KBR
KBR, Inc.
KBR licenses proprietary process technologies (ammonia, plastics recycling, lithium extraction) to customers.
|
$5.57B |
$42.80
-0.99%
|
|
PI
Impinj, Inc.
NXP patent settlement licenses IP revenue; licensing is a direct revenue stream.
|
$5.14B |
$191.17
+8.14%
|
|
COGT
Cogent Biosciences, Inc.
Cogent engages in Intellectual Property Licensing via a license arrangement with Plexxikon for bezuclastinib, constituting Intellectual Property Licensing.
|
$4.79B |
$34.51
+0.72%
|
|
ALKS
Alkermes plc
Intellectual property licensing and royalty arrangements with Janssen Biotech and Biogen.
|
$4.62B |
$28.79
+2.80%
|
|
FOLD
Amicus Therapeutics, Inc.
The company engages in licensing and IP-focused transactions (e.g., DMX-200 license and IP protections for Galafold), mapping to Intellectual Property Licensing.
|
$4.39B |
$14.27
+0.11%
|
|
LCID
Lucid Group, Inc.
Intellectual Property Licensing; licensing Lucid's tech to Aston Martin and other OEM discussions.
|
$4.17B |
$13.58
+5.43%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Ligand monetizes its proprietary technologies and licenses IP to pharma/biotech partners, generating royalty streams.
|
$3.76B |
$195.47
+1.79%
|
|
KFY
Korn Ferry
Licensing of Korn Ferry's IP and proprietary intelligence/data assets.
|
$3.44B |
$66.67
+1.43%
|
|
CNTA
Centessa Pharmaceuticals plc
Exclusive license agreement for LockBody with Genmab constitutes intellectual property licensing activity.
|
$3.09B |
$22.89
-0.56%
|
|
IPAR
Inter Parfums, Inc.
Interparfums licenses intellectual property/assets (brands/fragrances) to third parties as a core revenue stream.
|
$2.75B |
$87.51
+2.17%
|
|
BEAM
Beam Therapeutics Inc.
Beam licenses complementary gene editing technologies (e.g., prime editing, Cas12b, RNA base editing), constituting an Intellectual Property Licensing activity.
|
$2.72B |
$28.43
+5.92%
|
|
LION
Lionsgate Studios Corp.
Lionsgate licenses its intellectual property and related assets to third parties, contributing to its revenue through IP licensing.
|
$2.58B |
$8.53
-4.32%
|
|
CLVT
Clarivate Plc
Derwent IP data and related platforms involve Intellectual Property Licensing to customers.
|
$2.41B |
$3.38
-0.15%
|
|
BB
BlackBerry Limited
BB licenses its intellectual property and AI/ML patents via the Licensing division, representing an IP licensing revenue stream.
|
$2.30B |
$3.91
+0.77%
|
|
MESO
Mesoblast Limited
Intellectual property licensing and royalty income from collaborations (e.g., JCR, Takeda).
|
$2.11B |
$18.58
+1.59%
|
|
ADEA
Adeia Inc.
Adeia's primary business model is Intellectual Property Licensing, licensing a large portfolio of patents and IP assets.
|
$2.02B |
$18.47
+0.16%
|
|
TGI
Triumph Group, Inc.
Triumph leverages proprietary IP in its aftermarket and platform-specific components, aligning with IP Licensing themes.
|
$2.01B |
$26.01
|
|
PRKS
United Parks & Resorts Inc.
Engages in IP/licensing arrangements around its park brands and content, aligning with Intellectual Property Licensing.
|
$1.94B |
$36.78
+4.55%
|
|
WBTN
WEBTOON Entertainment Inc. Common stock
Licensing of intellectual property/assets to partners (e.g., Disney/Marvel/Star Wars) for broader media expansion.
|
$1.79B |
$13.96
+1.97%
|
|
WLYB
John Wiley & Sons, Inc.
Intellectual Property Licensing: licensing of IP/content to partners and AI/data licensing arrangements.
|
$1.74B |
$31.20
-5.51%
|
|
FBYD
Falcon's Beyond Global, Inc. Class A Common Stock
Intellectual property licensing supports cross-channel monetization of IP assets.
|
$1.67B |
$13.81
+0.36%
|
|
PCT
PureCycle Technologies, Inc.
PureCycle licenses the dissolution purification technology from Procter & Gamble, constituting a core IP licensing facet of the business.
|
$1.66B |
$9.44
+2.28%
|
|
WINA
Winmark Corporation
Brand IP licensing of the resale brands aligns with intellectual property licensing.
|
$1.51B |
$438.03
+3.24%
|
|
RDW
Redwire Corporation
Space-derived intellectual property and licensing (e.g., crystal forms) align with 'Intellectual Property Licensing'.
|
$1.48B |
$10.51
+2.44%
|
|
RLAY
Relay Therapeutics, Inc.
Relay pursues intellectual property licensing and asset licensing (e.g., lirafugratinib licensing) as a business activity.
|
$1.36B |
$8.12
+3.37%
|
|
ANAB
AnaptysBio, Inc.
Revenues include licensing and monetization of royalties related to external assets (IP licensing).
|
$1.21B |
$43.80
+1.39%
|
|
NVAX
Novavax, Inc.
Novavax monetizes its intellectual property through licensing and milestone/royalty arrangements with partners (e.g., Sanofi).
|
$1.18B |
$7.41
+2.14%
|
|
INBX
Inhibrx Biosciences, Inc.
License/IP assets licensing with third parties (Scithera) for non-dilutive funding potential.
|
$1.11B |
$78.03
+1.49%
|
|
MNMD
Mind Medicine (MindMed) Inc.
Exclusive licensing of Catalent's Zydis ODT technology represents Intellectual Property Licensing.
|
$1.03B |
$13.36
-1.62%
|
|
XNCR
Xencor, Inc.
Business relies on licensing XmAb technology to partners with royalty/milestone monetization.
|
$1.02B |
$13.83
-3.08%
|
|
ABUS
Arbutus Biopharma Corporation
The company licenses its LNP technology and pursues IP litigation, making Intellectual Property Licensing a direct business line.
|
$948.91M |
$4.58
-7.58%
|
|
SLDP
Solid Power, Inc.
SLDP licenses its electrolyte technology and related cell manufacturing know-how to partners, fitting Intellectual Property Licensing.
|
$931.80M |
$5.08
-1.17%
|
|
SKYT
SkyWater Technology, Inc.
Intellectual property licensing could be a revenue stream tied to IP co-development with customers.
|
$866.20M |
$18.20
-1.52%
|
|
NRGV
Energy Vault Holdings, Inc.
Exclusive IP licensing revenue (B-Vault IP) fits Intellectual Property Licensing.
|
$796.33M |
$5.79
+17.58%
|
|
SCHL
Scholastic Corporation
Intellectual property licensing of core franchises and characters beyond publishing.
|
$764.22M |
$31.57
+3.85%
|
|
ZBIO
Zenas BioPharma, Inc.
Company engages in IP licensing and collaboration revenue with multiple partners.
|
$699.45M |
$15.02
-9.60%
|
|
AIP
Arteris, Inc.
Arteris licenses NoC interconnect IP to semiconductor designers, making IP licensing a core revenue source.
|
$692.21M |
$17.63
+8.63%
|
|
PHCI
Panamera Holdings Corporation
PHCI's binding LOI/license for Rain Cage's carbon conversion technology constitutes intellectual property licensing.
|
$639.01M |
$8.00
|
|
NPWR
NET Power Inc.
Net Power's business model centers on licensing its Net Power Cycle IP to partners for commercial deployment.
|
$567.79M |
$2.54
-2.12%
|
|
CEVA
CEVA, Inc.
CEVA's core business is IP licensing for DSPs, NPUs and wireless IP, making Intellectual Property Licensing a primary revenue source.
|
$552.87M |
$23.71
+2.42%
|
|
HCKT
The Hackett Group, Inc.
Intellectual Property Licensing – licensing of Gen AI platforms/IP to clients and partners via the JV and related engagements.
|
$545.81M |
$20.05
+1.06%
|
|
LWLG
Lightwave Logic, Inc.
LWLG derives revenue from licensing its electro-optic polymer technology and providing technology transfers.
|
$493.17M |
$3.96
+3.81%
|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 licensing and exclusive rights indicate Intellectual Property Licensing activity.
|
$493.16M |
$30.80
+3.29%
|
|
RSVR
Reservoir Media, Inc.
Intellectual property licensing captures the broader IP licensing activity around music catalogs and related assets.
|
$488.41M |
$7.42
-0.47%
|
|
CRNC
Cerence Inc.
Cerence licenses its AI/IP assets to customers and partners, aligning with intellectual property licensing themes.
|
$480.41M |
$11.76
+6.04%
|
|
LENZ
LENZ Therapeutics, Inc.
LENZ engages in intellectual property licensing with international deals (Greater China, Southeast Asia, Canada), forming a core IP licensing revenue and moat.
|
$470.04M |
$16.39
-0.55%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra engages in licensing of IP and out-licensing of pre-clinical assets; fits Intellectual Property Licensing.
|
$468.17M |
$8.34
|
|
SIGA
SIGA Technologies, Inc.
SIGA licenses intellectual property (monoclonal antibodies) to advance its pipeline, fitting Intellectual Property Licensing.
|
$457.56M |
$6.66
+4.15%
|
|
PRTC
PureTech Health plc
Portfolio royalties and milestones from KarXT/Cobenfy fall under Intellectual Property Licensing.
|
$429.19M |
N/A
|
|
AMCX
AMC Networks Inc.
Licenses intellectual property across platforms, including IP libraries and franchises.
|
$412.15M |
$9.02
-5.05%
|
|
GRVY
Gravity Co., Ltd.
Ragnarok IP licensing is a core monetization channel, enabling merchandise and cross-media licensing.
|
$412.07M |
$58.13
-1.96%
|
|
ADCT
ADC Therapeutics S.A.
The company derives license revenues and royalties from partnerships, fitting Intellectual Property Licensing.
|
$400.50M |
$3.52
-0.98%
|
|
BYRN
Byrna Technologies Inc.
LATAM divestiture into licensing/distribution suggests material IP licensing revenue.
|
$393.91M |
$17.46
+0.66%
|
|
VALU
Value Line, Inc.
Intellectual property licensing related to Value Line's proprietary research technology and rankings.
|
$356.18M |
$37.88
+0.05%
|
|
ACTG
Acacia Research Corporation
Company monetizes patented portfolios via licensing and enforcement, core IP licensing business.
|
$350.10M |
$3.73
+2.89%
|
|
CLLS
Cellectis S.A.
Cellectis licenses TALEN IP and related technologies (e.g., to Iovance), reflecting an IP licensing revenue/strategy.
|
$327.31M |
$4.39
-3.30%
|
|
FCCN
Spectral Capital Corporation
Revenue from IP monetization through licensing is a direct business line.
|
$317.67M |
$3.99
|
|
ZH
Zhihu Inc.
Intellectual property licensing for branded content and AI/IP assets.
|
$314.89M |
$3.50
+2.79%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
The company monetizes IP via licensing/royalties (e.g., MAVYRET royalties and related licensing actions), aligning with Intellectual Property Licensing.
|
$297.37M |
$13.57
-2.44%
|
|
XPER
Xperi Inc.
Intellectual Property Licensing is a core revenue and strategic lever for Xperi through its technology IP.
|
$285.43M |
$6.12
-0.73%
|
|
QSG
QuantaSing Group Ltd
The company develops IPs and monetizes them through licensing arrangements, including exclusive and nonexclusive IP licenses.
|
$277.55M |
$5.81
+13.70%
|
|
SKYX
SKYX Platforms Corp.
Intellectual property licensing for SKYX's plug-and-play technology (licensing revenue).
|
$241.84M |
$2.17
|
|
MRAM
Everspin Technologies, Inc.
Revenue from licensing IP and IP monetization, a material revenue stream for the company.
|
$240.96M |
$12.23
+14.88%
|
|
INV
Innventure, Inc.
Innventure licenses technologies and IP from MNCs, making Intellectual Property Licensing a core business activity.
|
$230.89M |
$4.42
-5.04%
|
|
OABI
OmniAb, Inc.
OmniAb's business model centers on licensing its Biological Intelligence platforms and IP to partners, supported by milestone and royalty economics.
|
$227.00M |
$1.83
-0.81%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
Strategic review emphasizes licensing IP/assets and monetizing IP, fitting Intellectual Property Licensing.
|
$206.13M |
$4.47
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet engages in licensing of its denifanstat IP with Ascletis for China, indicating an IP licensing business activity.
|
$180.17M |
$5.54
+0.09%
|
|
EDIT
Editas Medicine, Inc.
Intellectual Property Licensing: monetization of IP through licensing deals with Vertex and DRI.
|
$178.94M |
$2.04
+2.76%
|
|
SRM
SRM Entertainment, Inc.
SRM engages in IP licensing/transfer of IP assets to create products, aligning with Intellectual Property Licensing.
|
$177.61M |
$10.30
|
|
DERM
Journey Medical Corporation
Journey Medical monetizes its intellectual property via licensing/out-licensing deals (e.g., Emrosi and other assets).
|
$173.57M |
$7.17
+0.63%
|
|
PLBY
Playboy, Inc.
Intellectual property licensing of Playboy assets to partners/licensees is a direct business line.
|
$170.24M |
$1.86
+4.19%
|
|
SAVA
Cassava Sciences, Inc.
Exclusive license agreement with Yale University — IP Licensing activity directly related to simufilam.
|
$154.10M |
$3.23
+1.10%
|
|
IKT
Inhibikase Therapeutics, Inc.
Company holds intellectual property and licensing activities around its programs (IKT-001Pro and risvodetinib).
|
$149.78M |
$2.04
+1.24%
|
Showing page 1 of 3 (217 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
